Background Peroxisome proliferator activated receptor γ （PPARγ） is a ligand-activated transcription factor. Activation of PPARγ has recently been demonstrated to inhibit various tumor cells growth, progression an...Background Peroxisome proliferator activated receptor γ （PPARγ） is a ligand-activated transcription factor. Activation of PPARγ has recently been demonstrated to inhibit various tumor cells growth, progression and metastasis. E-cadherin-mediated cell adhesion system is now considered to be an “invasion suppressor system” in cancer tissues. Matrix metalloproteinases-2 （MMP-2） is a prerequisite for metastasizing tumor cells. However their correlation is still unknown in gastric carcinoma. The aim of this study was to assess the expression of PPAR7, E-cadherin, MMP-2 and their correlation in gastric carcinoma and metastases. Methods Gastric carcinoma tissues and their corresponding lymph nodes with metastases and the adjacent non-tumor tissues were obtained from 54 patients with gastric cancer who underwent gastrectomy. Expression of PPARγ, E-cadherin and MMP-2 was assessed by immunohistochemical staining. Results The nuclear expression level of PPARγ in neoplastic cells was significantly lower than that in the normal controls （P〈0.001）, with the expression of PPARγ being weaker in primary tumors compared with that in metastases. In all neoplastic cells, E-cadherin was expressed with abnormal patterns （cytoplasm pattern, cytoplasm and membrane pattern or absent）, compared with normal cells where E-cadherin was expressed with a normal pattern （membrane pattern）. Compared with the normal tissues, the expression level of E-cadherin decreased in primary tumors and further decreased in metastases （P〈0.001）. Membrane staining of MMP-2 was detected in the foveolar epithelia of normal gastric mucosa, whereas predominant cytoplasm staining of MMP-2 was found in malignant tissues. The expression of MMP-2 was stronger in metastatic tissues than in primary tumors. In neoplastic foci the expression of PPARγ was negatively correlated with MMP-2 expression （P〈0.05）. However, there was no correlation between E-cadherin and PPARγ or MM P-2 expression. Conclusions Down-regulation of PPAR�展开更多
目的探讨腹腔镜下射频消融术(LRFA)在肝癌患者中的临床应用价值及其对血清血管内皮生长因子(VEGF)和基质金属蛋白酶-2(MMP-2)的影响。方法收集2012年1月-2013年12月该院收治的晚期原发性肝癌患者120例,将患者随机分为LRFA组和对照组。L...目的探讨腹腔镜下射频消融术(LRFA)在肝癌患者中的临床应用价值及其对血清血管内皮生长因子(VEGF)和基质金属蛋白酶-2(MMP-2)的影响。方法收集2012年1月-2013年12月该院收治的晚期原发性肝癌患者120例,将患者随机分为LRFA组和对照组。LRFA组患者采用LRFA治疗后,继续采用FOLFOX4方案化疗;对照组仅采用PIAF方案化疗。主要观察指标为健康相关生存质量(HRQL)、实体瘤疗效评价(RECIST)等级、无进展生存期和2年死亡率;次要观察指标为血清VEGF和MMP-2水平。结果与对照组相比,LRFA组患者病情进展率明显降低(28.33%vs 50.00%,P=0.015);无进展生存期明显延长(500 d vs 380 d,P=0.013);临床干预后6个月时HRQL明显增高[(80.33±5.84)vs(65.87±9.59),P=0.000];临床干预后7、14和28天以及6个月时VEGF明显降低(P值均为0.000);临床干预后14和28天以及6个月时MMP-2明显降低(P值分别为0.003、0.001和0.000)。结论 LRFA明显改善了肝癌患者临床预后,并显著降低患者VEGF、MMP-2水平。展开更多
基金the grants from the National Natural Science Foundation of China (No. 30671904 and No. 30670949)the Doctor Subjects Foundation of the Ministry of Education of the People's Republic of China (No. 20060558010).
文摘Background Peroxisome proliferator activated receptor γ （PPARγ） is a ligand-activated transcription factor. Activation of PPARγ has recently been demonstrated to inhibit various tumor cells growth, progression and metastasis. E-cadherin-mediated cell adhesion system is now considered to be an “invasion suppressor system” in cancer tissues. Matrix metalloproteinases-2 （MMP-2） is a prerequisite for metastasizing tumor cells. However their correlation is still unknown in gastric carcinoma. The aim of this study was to assess the expression of PPAR7, E-cadherin, MMP-2 and their correlation in gastric carcinoma and metastases. Methods Gastric carcinoma tissues and their corresponding lymph nodes with metastases and the adjacent non-tumor tissues were obtained from 54 patients with gastric cancer who underwent gastrectomy. Expression of PPARγ, E-cadherin and MMP-2 was assessed by immunohistochemical staining. Results The nuclear expression level of PPARγ in neoplastic cells was significantly lower than that in the normal controls （P〈0.001）, with the expression of PPARγ being weaker in primary tumors compared with that in metastases. In all neoplastic cells, E-cadherin was expressed with abnormal patterns （cytoplasm pattern, cytoplasm and membrane pattern or absent）, compared with normal cells where E-cadherin was expressed with a normal pattern （membrane pattern）. Compared with the normal tissues, the expression level of E-cadherin decreased in primary tumors and further decreased in metastases （P〈0.001）. Membrane staining of MMP-2 was detected in the foveolar epithelia of normal gastric mucosa, whereas predominant cytoplasm staining of MMP-2 was found in malignant tissues. The expression of MMP-2 was stronger in metastatic tissues than in primary tumors. In neoplastic foci the expression of PPARγ was negatively correlated with MMP-2 expression （P〈0.05）. However, there was no correlation between E-cadherin and PPARγ or MM P-2 expression. Conclusions Down-regulation of PPAR�
文摘目的探讨腹腔镜下射频消融术(LRFA)在肝癌患者中的临床应用价值及其对血清血管内皮生长因子(VEGF)和基质金属蛋白酶-2(MMP-2)的影响。方法收集2012年1月-2013年12月该院收治的晚期原发性肝癌患者120例,将患者随机分为LRFA组和对照组。LRFA组患者采用LRFA治疗后,继续采用FOLFOX4方案化疗;对照组仅采用PIAF方案化疗。主要观察指标为健康相关生存质量(HRQL)、实体瘤疗效评价(RECIST)等级、无进展生存期和2年死亡率;次要观察指标为血清VEGF和MMP-2水平。结果与对照组相比,LRFA组患者病情进展率明显降低(28.33%vs 50.00%,P=0.015);无进展生存期明显延长(500 d vs 380 d,P=0.013);临床干预后6个月时HRQL明显增高[(80.33±5.84)vs(65.87±9.59),P=0.000];临床干预后7、14和28天以及6个月时VEGF明显降低(P值均为0.000);临床干预后14和28天以及6个月时MMP-2明显降低(P值分别为0.003、0.001和0.000)。结论 LRFA明显改善了肝癌患者临床预后,并显著降低患者VEGF、MMP-2水平。
